| Acinetobacter infection | Actinomycosis | Active Bacterial Core surveillance (ABCs) | Aerobic organisms | Al Kumrah virus | Anaplasmosis | Animal importation regulations | Anthrax | Antimicrobial resistance | Arctic Investigations Program | Arenaviruses | Argentine hemorrhagic fever | Avipox | Biosafety Level 4 laboratory | Bioterrorism preparedness | Blood, organ, and other tissue safety | Bolivian hemorrhagic fever | Botulism | Bovine spongiform encephalopathy | Brazilian hemorrhagic fever | Buffalopox | Bunyaviruses | Buruli ulcer |Campylobacter | Candidiasis | Carbapenem- producing Klebsiella pneumoniae | CDC Drug Service | Central line bloodstream infection | Chikungunya fever | Cholera | Chronic fatigue syndrome | Chronic wasting disease | Clostridium difficileinfection | Community mitigation | Cowpox | Creutzfeldt-Jakob disease | Crimean-Congo hemorrhagic fever | Cryptococcus | Cryptosporidium | Dengue fever | Diarrheal diseases | Eastern equine encephalitis | Ebola hemorrhagic fever | Ehrlichiosis | Emerging Infections Program | Emerging Infectious Diseases journal | Epidemiology and Laboratory Capacity for Infectious Diseases Program | E. coli infection | Equine morbillivirus | Flaviviruses | Filoviruses | Foodborne diseases | FoodNet | Food safety | Giardia | Glanders | Global migration and quarantine | Green monkey disease | Guillain-Barré syndrome | Guanarito virus | Hansen’s disease (leprosy) | Hantavirus | Healthy travel | Hendra virus disease | Immigrant, refugee, and migrant healthNATIONAL | Immunization safetyCENTER | Japanese FOR encephalitis | Junin virus | Kawasaki disease | Klebsiella pneumoniae in healthcare settingsEMERGING | Korean hemorrhagic AND fever ZOONOTIC | Kuru | Kyasanur INFECTIOUS forest disease | Laboratory DISEASES quality | Laboratory Response Network | Lassa fever | Leptospirosis | Listeriosis | Lujo virus | Lyme disease | Lymphocytic choriomeningitis | Machupo virus | Marburg hemorrhagic fever | Melioidosis | MRSA (methicillin-resistant Staphylococcus aureus) infection | Milker’s nodule | Molluscum contagiosum | Monkeypox | Mucormycosis | Mycobacterium abscessus in healthcareSTRATEGIC settings | National Healthcare Safety Network | PLANNaegleria fowleri | National Antimicrobial Resistance Monitoring System (NARMS) | Nipah virus encephalitis | Nocardiosis | Omsk hemorrhagic fever | Orf virus | Parapox | Pasturella species | Plague | Prion diseases | Pseudocowpox | PulseNet | Puumala2012-2017 virus | Q fever | Quarantine stations | Rabies | Raccoonpox | Rat-bite fever | Recreational water illnesses | Reye syndrome | Rickettsial diseases | Rift Valley fever | Rocky Mountain spotted fever | Sabia virus | Safe Water System | Salmonella | Sealpox | Select Agent Program | Shiga toxin-producing E. coli | Shigella | Skunkpox | Slow virus | Smallpox | Squirrelpox | Tanapox | Tickborne encephalitis | Tularemia | Typhoid fever | Undulant fever (brucellosis) | Unexplained fatal illness | Urinary tract infection (catheter-associated) | Vaccinia | Vaccine Adverse Event Reporting System (VAERS) | Vaccine safety | Vibrio vulnificus | Viral hemorrhagic fevers | Volepox | Waterborne diseases | West Nile virus | Western equine encephalitis | Xenotropic murine leukemia virus-related virus | The Yellow Book | Yellow fever | Yersiniosis | Zika virus | Zoonosis | Acinetobacter infection | Actinomycosis | Active Bacterial Core surveillance (ABCs) | Aerobic organisms | Al Kumrah virus | Anaplasmosis | Animal importation regulations | Anthrax | Antimicrobial resistance | Arctic Investigations Program | Arenaviruses | Argentine hemorrhagic fever | Avipox | Biosafety Level 4 laboratory | Bioterrorism preparedness | Blood, organ, and other tissue safety | Bolivian hemorrhagic fever | Botulism | Bovine spongiform encephalopathy | Brazilian hemorrhagic fever | Buffalopox | Bunyaviruses | Buruli ulcer |Campylobacter | Candidiasis | Carbapenem- producing Klebsiella pneumoniae | CDC Drug Service | Central line bloodstream infection | Chikungunya fever | Cholera | Chronic fatigue syndrome | Chronic wasting disease | Clostridium difficileinfection | Community mitigation | Cowpox | Creutzfeldt-Jakob disease | Crimean-Congo hemorrhagic fever | Cryptococcus | Cryptosporidium | Dengue fever | Diarrheal diseases | Eastern equine encephalitis | Ebola hemorrhagic fever | Ehrlichiosis | Emerging Infections Program | Emerging Infectious Diseases journal | Epidemiology and Laboratory Capacity for Infectious Diseases Program | E. coli infection | Equine morbillivirus | Flaviviruses | Filoviruses | Foodborne diseases | FoodNet | Food safety | Giardia | Glanders | Global migration and quarantine | Green monkey disease | Guillain-Barré syndrome | Guanarito virus | Hansen’s disease (leprosy) | Hantavirus | Healthy travel | Hendra virus disease | Immigrant, refugee, and migrant health | Immunization safety | Japanese encephalitis | Junin virus | Kawasaki disease | Klebsiella pneumoniae in healthcare settings | Korean hemorrhagic fever | Kuru | Kyasanur forest disease | Laboratory quality | Laboratory Response Network | Lassa fever | Leptospirosis | Listeriosis | Lujo virus | Lyme disease | Lymphocytic choriomeningitis | Machupo virus | Marburg hemorrhagic fever | Melioidosis | MRSA (methicillin-resistant Staphylococcus aureus) infection | Milker’s nodule | Molluscum contagiosum | Monkeypox | Mucormycosis | Mycobacterium abscessus in healthcare settings | National Healthcare Safety Network | Naegleria fowleri | National Antimicrobial Resistance Monitoring System (NARMS) | Nipah virus encephalitis | Nocardiosis | Omsk hemorrhagic fever | Orf virus | Parapox | Pasturella species | Plague | Prion diseases | PseudocowpoxNational |Center PulseNet for |Emerging Puumala andvirus Zoonotic | Q fever Infectious| Quarantine Diseases stations | Rabies | Raccoonpox | Rat-bite fever | Recreational water Office of the Director illnesses | Reye syndrome | Rickettsial diseases | Rift Valley fever | Rocky Mountain spotted fever | Sabia virus | Safe Water System | Salmonella | Sealpox | CS234429-A Select Agent Program | Shiga toxin-producing E. coli | Shigella | Skunkpox | Slow virus | Smallpox | Squirrelpox | Tanapox | Tickborne encephalitis | Tularemia | Typhoid fever | Undulant fever (brucellosis) | Unexplained fatal illness | Urinary tract infection (catheter-associated) | Vaccinia | Vaccine Adverse CDC scientists in 2011 study bats in Uganda to learn more about their relationship to Marburg virus which, like Ebola virus, can cause a rare but deadly hemorrhagic fever in humans and other primates. NCEZID STRATEGIC PLAN 2012-2017 The National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) was established in 2010, with a mission and scientific activities that trace back to the earliest days of the Centers for Disease Control and Prevention (CDC). This document is a strategic roadmap for the work necessary during the next 5 years to realize the Center’s vision—prevent infection, protect people, and save lives. NCEZID is responsible for the prevention and control of a wide range of infectious diseases, including rare but deadly diseases like anthrax and VISION: Prevent infections, protect people, save lives Ebola hemorrhagic fever, and more common illnesses like foodborne diseases and healthcare-associated infections. The Center’s expert staff MISSION: To reduce illness and manages a broad portfolio of science-based programs that also promote death associated with emerging and water safety, the health of migrating populations, and the identification zoonotic infectious diseases and to and control of diseases transmitted by animals and insects (e.g., rabies, protect against the unintentional Lyme disease). NCEZID works closely with the National Center for or intentional spread of infectious Immunization and Respiratory Diseases, the National Center for HIV/ diseases AIDS, Viral Hepatitis, STD, and TB Prevention, and other parts of CDC to fulfill the agency’s commitment to protect against the spread of all infectious diseases. NCEZID is one of the agency’s principal sources of epidemiologic and laboratory expertise about bacterial, viral, and fungal pathogens as well as infectious diseases of unknown origin. State and local health departments, other federal agencies, and foreign ministries of health look to NCEZID to assist with wide-ranging problems—from illness and death in 28 states caused by Listeria-contaminated cantaloupes, to an outbreak of anthrax in hippos and humans in Kenya, to rising rates of tuberculosis among people immigrating to the United States, to new outbreaks of dengue in south Florida. And, it is primarily because NCEZID’s diverse workforce includes a correspondingly broad spectrum of infectious disease expertise (see insert, pg. 2) that mysterious illnesses are identified, outbreaks are contained, and lives are saved. None of this work could happen without an ever-expanding extensive network of partnerships. NCEZID collaborates with many public and private partners, most notably federal, state, and local public health departments, public health organizations, academia, industry, and global multilateral organizations and ministries of health. NCEZID STRATEGIC PLAN 2012-2017 1 About the Strategic Plan As noted by the Institute of Medicine, the “global interconnectedness” that has evolved during the past several decades has caused infectious pathogens to “…emerge more frequently, spread greater distances, pass more eas- The success of NCEZID’s strategic plan ily between humans and animals, and will require continued